Provided by Tiger Trade Technology Pte. Ltd.

Ionis Pharmaceuticals

54.21
-1.4400-2.59%
Post-market: 54.210.00000.00%17:36 EDT
Volume:2.18M
Turnover:119.32M
Market Cap:9.01B
PE:-15.58
High:56.16
Open:55.94
Low:54.16
Close:55.65
52wk High:86.74
52wk Low:50.01
Shares:166.18M
Float Shares:161.92M
Volume Ratio:0.49
T/O Rate:1.34%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4800
EPS(LYR):-2.3812
ROE:-105.50%
ROA:-12.42%
PB:20.49
PE(LYR):-22.77

Loading ...

Ionis Pharmaceuticals - to Initiate Phase 3 Champion Study of Obudanersen Before End of 2026

THOMSON REUTERS
·
Jul 06

Ionis Pharmaceuticals - Topline Data from Reveal Study Expected in Second Half of 2027

THOMSON REUTERS
·
Jul 06

Ionis Pharmaceuticals - Adult Cohort Expected to Complete Enrollment in Q3 2026

THOMSON REUTERS
·
Jul 06

Ionis Completes Enrollment in Pivotal Cohort of the Phase 3 Reveal Study Evaluating Obudanersen in Angelman Syndrome

THOMSON REUTERS
·
Jul 06

Ionis EVP, Chief Clinical Development Officer Eugene Schneider Disposes of 26,000 Shares for $2.11 Million

Reuters
·
Jul 01

Ionis EVP Research Eric Swayze Sells 10,602 Shares for $839,082.60

Reuters
·
Jun 27

Movement Alert|Ionis Pharmaceuticals Rises 5.32% in Regular Trading, Zilganersen Global Commercialization Accelerates via Recordati Licensing Deal

Market Focus
·
Jun 26

Ionis Pharmaceuticals Inc : Piper Sandler Raises Target Price to $110 from $100

THOMSON REUTERS
·
Jun 25

Ionis Pharmaceuticals is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Jun 25

Wells Fargo Sticks to Its Buy Rating for Ionis Pharmaceuticals (IONS)

TIPRANKS
·
Jun 25

Ionis Licenses Alexander Disease Drug Zilganersen to Recordati Outside US for $30 Million Upfront

Reuters
·
Jun 25

Ionis Pharmaceuticals - Plans Independent U.S. Launch of Zilganersen; FDA Pdufa Date Set for September 22

THOMSON REUTERS
·
Jun 25

Ionis Announces License Agreement with Recordati for Zilganersen in Alexander Disease (axd) in All Countries Outside the U.S.

THOMSON REUTERS
·
Jun 25

Ionis Pharmaceuticals - to Retain U.S. Commercial Rights and Lead Global Development of Zilganersen

THOMSON REUTERS
·
Jun 25

Analysts Are Bullish on These Healthcare Stocks: Ionis Pharmaceuticals (IONS), uniQure (QURE)

TIPRANKS
·
Jun 25

Ionis Pharmaceuticals price target raised to $75 from $74 at Goldman Sachs

TIPRANKS
·
Jun 25

Ionis Pharmaceuticals - Tryngolza Available in 50 Mg or 80 Mg Dose, Self-administered Monthly

THOMSON REUTERS
·
Jun 25

Tryngolza® (olezarsen) Approved by the FDA as the First and Only Treatment to Reduce Triglycerides and the Risk of Acute Pancreatitis in Patients with Severe Hypertriglyceridemia (shtg)

THOMSON REUTERS
·
Jun 25

Ionis Pharmaceuticals - Tryngolza to be Available in U.S. for Shtg in July

THOMSON REUTERS
·
Jun 25

FDA: Approves First Treatment Shown to Reduce the Risk of Acute Pancreatitis in Adults with Severe Hypertriglyceridemia

THOMSON REUTERS
·
Jun 25